MCOLN1 and ovarian cancer: In patient-derived ovarian cancer cells exhibiting cisplatin resistance, the inhibition of TRPML1 was observed to reduce the cellular content of arginine, which had been elevated by cisplatin treatment, as determined through MS/MS analysis.